A simplified method of calculating cPRA for kidney allocation application in Hong Kong: a retrospective study

Transpl Int. 2017 Dec;30(12):1234-1242. doi: 10.1111/tri.13015. Epub 2017 Aug 23.

Abstract

Calculated panel reactive antibody (cPRA) represents possibility of encountering an incompatible donor for organ transplant candidates and has gradually replaced traditional PRA as a measurement of sensitization level. We tested two cPRA calculation methods on a cohort of renal candidate (n = 613). HLA typing of 563 Chinese deceased renal donors was used to estimate allele and haplotype frequencies of Hong Kong donor pool. The OPTN formula was adopted to generate cPRA (cPRA (freq)). We also incorporated a computer script to compare unacceptable antigens of patients against HLA phenotype of donors. The cPRA based on historical donor filtering was the percentage of filter out count over total number of donors (cPRA (filter)). Values of cPRA (freq) and cPRA (filter) showed almost perfect agreement with Lin's correlation coefficient equal to 1.000. SD of bias was 0.6 cPRA point. Limit of agreement was 0.9 to -1.5 points difference. Furthermore, the poor agreement between our in-house cPRA and values from other online calculators indicated the necessity to use local population data for accurate cPRA calculation. Built-in donor filtering method was more practicable for Hong Kong due to factors such as cost and flexibility. An on-going donor pool can reflect population allele frequencies and permits efficient periodic update of cPRA.

Keywords: calculated panel reactive antibody; organ allocation; renal transplantation; sensitization; unacceptable antigen; virtual cross-match.

MeSH terms

  • Cohort Studies
  • Donor Selection / methods*
  • Female
  • Graft Rejection
  • Graft Survival
  • HLA Antigens / immunology*
  • Histocompatibility Testing / methods
  • Hong Kong
  • Humans
  • Isoantibodies / blood*
  • Kidney Transplantation / adverse effects
  • Kidney Transplantation / methods
  • Kidney Transplantation / mortality*
  • Male
  • Registries*
  • Retrospective Studies
  • Risk Assessment
  • Survival Analysis
  • Tissue and Organ Procurement / methods*
  • Transplantation Immunology

Substances

  • HLA Antigens
  • Isoantibodies